AAP
CLYM

Arax Advisory Partners’s Climb Bio CLYM Stock Holding History

Arax Advisory Partners’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-51
Closed -$110 – 5275
2026
Q1 		$110 Buy
+51
New +$294 ﹤0.01% 3606
2025
Q4 		– Sell
-53
Closed -$106 – 4608
2025
Q3 		$106 Buy
+53
New +$98 ﹤0.01% 3492

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Arax Advisory Partners's CLYM Position: Q2 2026 in Review

Arax Advisory Partners sold out of Climb Bio (CLYM) in Q2 2026, closing a stake of 51 shares — an estimated $110 sold.

Arax Advisory Partners first reported a position in CLYM in Q3 2025 and held it in 2 quarters. The position peaked at $110 in Q1 2026. 109 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • Arax Advisory Partners reported no remaining Climb Bio position as of Q2 2026 after selling out during the quarter.
  • Arax Advisory Partners sold 51 Climb Bio shares in Q2 2026, an estimated $110.
  • Arax Advisory Partners first reported a position in Climb Bio in Q3 2025 and held it in 2 quarters.
  • Arax Advisory Partners's Climb Bio position peaked at $110 in Q1 2026.
  • 109 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.